Letters: End the false economy of generic prescribing

The warning of adverse events linked to the use of generic drug alendronate in your article 'Side-effects of NICE-backed drug "wipe out cost savings"' (GP, 19 September) comes from a consultant physician.

It seems that NICE is not nice nor a patient-friendly regulatory body any more.

The UK is adapting policy to save money at the expense of patients' misery. Surely NICE can find a sensible alternative to this ridiculous false economy.

GPs are all too well aware of the adverse effects patients suffer from not only generic alendronate, but also many other cheap products pushed into the system. The incentive scheme is a failure and it is about time we reverted to prescribing branded, clean and well-tested pharmaceutical products ethically.

Dr Hari Nawal, Bedford.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

GP consultation

GP practices delivering 150,000 extra appointments per day compared with 2019

GP practices in England delivered 150,000 more appointments per working day in the...

Surgeon looking at a monitor in an operating theatre

NICE recommends non-invasive surgical procedure to target obesity

NICE has said that a non-invasive weight loss procedure should be used by the NHS...

GP trainee

Two training posts deliver one full-time GP on average, report warns

Two training posts are needed on average to deliver a single fully-qualified, full-time...

Dr Fiona Day

How to flourish as a GP by learning from the good and the difficult

Leadership and career coach Dr Fiona Day explains how GPs can grow and develop from...

Unhappy older woman sitting at home alone

Low mood – red flag symptoms

Low mood is a common presentation in primary care and can be a sign of a mental health...


PCN to take on GMS practice contract in landmark move for general practice

A GP practice in Hertfordshire could become the first to be run directly by a PCN...